Cargando…
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
BACKGROUND: Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model for predicting sorafenib response and overall survival (OS). METHODS: This prosp...
Autores principales: | Kim, Hwi Young, Lee, Dong Hyeon, Lee, Jeong-Hoon, Cho, Young Youn, Cho, Eun Ju, Yu, Su Jong, Kim, Yoon Jun, Yoon, Jung-Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859435/ https://www.ncbi.nlm.nih.gov/pubmed/29558905 http://dx.doi.org/10.1186/s12885-018-4211-2 |
Ejemplares similares
-
Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019) -
Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
por: Lee, Seulki, et al.
Publicado: (2018) -
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib
por: Yoo, Jeong-Ju, et al.
Publicado: (2018) -
Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients
por: Nam, Joon Yeul, et al.
Publicado: (2017) -
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
por: Chang, Young, et al.
Publicado: (2020)